Starlight Cardiovascular is focused on creating innovative medical devices specifically designed for infants suffering from Congenital Heart Disease (CHD). Their portfolio includes a range of advanced technologies aimed at addressing the unique challenges associated with treating this condition in newborns. The company emphasizes the importance of developing solutions that are not only effective but also tailored to the delicate physiology of young patients, ensuring that their devices can provide safe and reliable interventions.

The company’s research and development efforts are grounded in a strong scientific foundation, leveraging cutting-edge techniques and materials to enhance the performance of their devices. Starlight Cardiovascular is committed to advancing the field of pediatric cardiology by integrating the latest advancements in medical technology, which may include minimally invasive approaches and biocompatible materials. This focus on innovation aims to improve outcomes for children with CHD, ultimately contributing to better long-term health and quality of life for these patients.

United States

Starlight Cardiovascular is developing much needed tools and devices to treat pediatric Congenital Heart Defects (CHDs). Approximately 1.3 million babies are born each year with a CHD. Most of the tools used to treat these children were designed for adult conditions and anatomy, limiting their utility for pediatric patients. Starlight Cardiovascular is developing a portfolio of devices designed and tested specifically for pediatric CHD with the goals of improving morbidity, mortality, and access to care.

Starlight Cardiovascular

Company Details